ESMO (European Society for Medical Oncology) shared a post on LinkedIn:
“Additional analysis from the NIAGARA trial reported survival benefits of perioperative durvalumab with neoadjuvant chemotherapy in both patients with muscle-invasive Bladder Cancer (MIBC) achieving a pathological complete response (pCR) and those not achieving a pCR, as well as a reduction of the risk of developing metastases and cancer-related death.
The novel data provide further support for the use of the immunotherapy-based treatment as a potential new option for cisplatin-eligible patients.
Read about the study results in the ESMO Daily Reporter.”
More posts featuring ESMO.